Please login to the form below

Not currently logged in
Email:
Password:

Astellas Pharma sees drop in Q2 income

Astellas reports a fall in income for the second quarter of 2011, as R&D and administrative expenses rise

Astellas Pharma, the Japanese pharmaceutical company, has posted a 36 per cent fall in net income to 25.1bn yen in the second quarter of 2011.

The company reported that net sales increase by 6 per cent to 251.6bn yen, boosted in part by its acquisition of OSI Pharmaceuticals in June 2010.

In Europe sales increased by 5 per cent in the quarter to 54.9bn yen, while Japanese sales rose by 139.3bn yen. Sales in the Americas increased by 21 per cent to 48.2bn for the quarter, while sales in Asia rose by 1.6 per cent to 9bn yen.

The company reported that second quarter R&D expenses had risen by 13 per cent to 43.5bn yen, while selling, general and administrative expenses increased by 11.5 per cent to 125.3bn yen for the quarter.

1st August 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics